JPWO2022129283A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022129283A5 JPWO2022129283A5 JP2023536951A JP2023536951A JPWO2022129283A5 JP WO2022129283 A5 JPWO2022129283 A5 JP WO2022129283A5 JP 2023536951 A JP2023536951 A JP 2023536951A JP 2023536951 A JP2023536951 A JP 2023536951A JP WO2022129283 A5 JPWO2022129283 A5 JP WO2022129283A5
- Authority
- JP
- Japan
- Prior art keywords
- pain
- pharmaceutical composition
- compound
- hydrogen atom
- alkyl group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000002193 Pain Diseases 0.000 claims 19
- 150000001875 compounds Chemical class 0.000 claims 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 12
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 11
- 239000008194 pharmaceutical composition Substances 0.000 claims 11
- 125000005843 halogen group Chemical group 0.000 claims 9
- 201000010099 disease Diseases 0.000 claims 6
- 208000035475 disorder Diseases 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 4
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 3
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 3
- 208000004296 neuralgia Diseases 0.000 claims 3
- 208000021722 neuropathic pain Diseases 0.000 claims 3
- 206010065390 Inflammatory pain Diseases 0.000 claims 2
- 208000010261 Small Fiber Neuropathy Diseases 0.000 claims 2
- 206010073928 Small fibre neuropathy Diseases 0.000 claims 2
- 150000001768 cations Chemical class 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 201000008482 osteoarthritis Diseases 0.000 claims 2
- 208000017692 primary erythermalgia Diseases 0.000 claims 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
- 206010003658 Atrial Fibrillation Diseases 0.000 claims 1
- 208000000094 Chronic Pain Diseases 0.000 claims 1
- 208000030939 Chronic inflammatory demyelinating polyneuropathy Diseases 0.000 claims 1
- 206010028391 Musculoskeletal Pain Diseases 0.000 claims 1
- 208000001294 Nociceptive Pain Diseases 0.000 claims 1
- JVADFCVBYOYMRX-UHFFFAOYSA-N [2-methyl-3-[1-[2-methyl-4-(trifluoromethoxy)phenyl]-4-oxo-6-(trifluoromethyl)-2H-pyrido[2,3-d]pyrimidin-3-yl]-6-oxopyridin-1-yl]methyl dihydrogen phosphate Chemical compound CC(C=C(C=C1)OC(F)(F)F)=C1N(CN1C(C=C2)=C(C)N(COP(O)(O)=O)C2=O)C(N=CC(C(F)(F)F)=C2)=C2C1=O JVADFCVBYOYMRX-UHFFFAOYSA-N 0.000 claims 1
- VWTOFRNSHHUBPP-UHFFFAOYSA-N [3-[1-(4-fluoro-2-methylphenyl)-4-oxo-6-(trifluoromethyl)-2H-quinazolin-3-yl]-2-methyl-6-oxopyridin-1-yl]methyl dihydrogen phosphate Chemical compound CC(C=C(C=C1)F)=C1N(CN1C(C=C2)=C(C)N(COP(O)(O)=O)C2=O)C2=CC=C(C(F)(F)F)C=C2C1=O VWTOFRNSHHUBPP-UHFFFAOYSA-N 0.000 claims 1
- YOEPKAJXVHOHLL-UHFFFAOYSA-N [3-[1-(4-fluoro-2-methylphenyl)-4-oxo-7-(trifluoromethyl)-2H-quinazolin-3-yl]-2-methyl-6-oxopyridin-1-yl]methyl dihydrogen phosphate Chemical compound CC(C=C(C=C1)F)=C1N(CN1C(C=C2)=C(C)N(COP(O)(O)=O)C2=O)C2=CC(C(F)(F)F)=CC=C2C1=O YOEPKAJXVHOHLL-UHFFFAOYSA-N 0.000 claims 1
- SQOAVOGMZCUHHE-UHFFFAOYSA-N [3-[6-chloro-1-(4-fluoro-2-methylphenyl)-4-oxo-2H-quinazolin-3-yl]-2-methyl-6-oxopyridin-1-yl]methyl dihydrogen phosphate Chemical compound CC(C=C(C=C1)F)=C1N(CN(C(C=C1)=C(C)N(COP(O)(O)=O)C1=O)C(C1=C2)=O)C1=CC=C2Cl SQOAVOGMZCUHHE-UHFFFAOYSA-N 0.000 claims 1
- 208000005298 acute pain Diseases 0.000 claims 1
- 201000005795 chronic inflammatory demyelinating polyneuritis Diseases 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 201000002342 diabetic polyneuropathy Diseases 0.000 claims 1
- 239000000835 fiber Substances 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000007824 polyneuropathy Effects 0.000 claims 1
- 230000002980 postoperative effect Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 1
- 208000009935 visceral pain Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063127341P | 2020-12-18 | 2020-12-18 | |
| US63/127,341 | 2020-12-18 | ||
| PCT/EP2021/086101 WO2022129283A1 (en) | 2020-12-18 | 2021-12-16 | Chemical compounds useful for inhibiting nav1.8 voltage-gated sodium channels and treating nav1.8 mediated diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024502231A JP2024502231A (ja) | 2024-01-18 |
| JPWO2022129283A5 true JPWO2022129283A5 (enrdf_load_html_response) | 2024-12-20 |
Family
ID=79025144
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023536951A Pending JP2024502231A (ja) | 2020-12-18 | 2021-12-16 | Ｎａｖ１．８電位依存性ナトリウムチャネルを阻害するためおよびＮａｖ１．８介在疾患を治療するために有用な化学化合物 |
Country Status (13)
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2692766C1 (ru) * | 2013-12-13 | 2019-06-27 | Вертекс Фармасьютикалз Инкорпорейтед | Пролекарства пиридонамидов, применяемые в качестве модуляторов натриевых каналов |
-
2021
- 2021-12-16 IL IL303795A patent/IL303795A/en unknown
- 2021-12-16 WO PCT/EP2021/086101 patent/WO2022129283A1/en not_active Ceased
- 2021-12-16 CA CA3202328A patent/CA3202328A1/en active Pending
- 2021-12-16 CN CN202180085151.XA patent/CN116710463A/zh active Pending
- 2021-12-16 EP EP21831047.2A patent/EP4262978A1/en active Pending
- 2021-12-16 JP JP2023536951A patent/JP2024502231A/ja active Pending
- 2021-12-16 PH PH1/2023/551406A patent/PH12023551406A1/en unknown
- 2021-12-16 AU AU2021403606A patent/AU2021403606B2/en active Active
- 2021-12-16 KR KR1020237023878A patent/KR20230121827A/ko active Pending
- 2021-12-16 MX MX2023007244A patent/MX2023007244A/es unknown
-
2023
- 2023-06-15 CL CL2023001750A patent/CL2023001750A1/es unknown
- 2023-06-18 SA SA523441263A patent/SA523441263B1/ar unknown
- 2023-06-21 CO CONC2023/0008049A patent/CO2023008049A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004506718A5 (enrdf_load_html_response) | ||
| US8394844B2 (en) | EP4 agonist | |
| JP2019510787A5 (enrdf_load_html_response) | ||
| CA2401984A1 (en) | Sulfur substituted aryldifluoromethylphosphonic acids as ptp-1b inhibitors | |
| BR112018005194B1 (pt) | Processo para preparar um composto antifúngico | |
| JP2014508106A (ja) | スフィンゴシン−１−リン酸−１受容体モジュレーターとしてのアルキンおよびアルケン誘導体 | |
| JPH06509100A (ja) | 抗炎症剤としてのピラゾロピリミジンおよびピリミジニルビスホスホン酸エステル類 | |
| US8497254B2 (en) | Oxadiazole derivatives as sphingosine 1-phosphate (S1P) receptor modulators | |
| JP5734952B2 (ja) | 新規なｅｐ４アゴニスト | |
| JP2013508385A5 (enrdf_load_html_response) | ||
| JP2013544821A (ja) | Ｓ１ｐ受容体モジュレーターとしての新規ホスホン酸 | |
| JP2014502273A (ja) | スフィンゴシン−１−リン酸（ｓ１ｐ）受容体モジュレーターとしての新規ベンジルアゼチジン誘導体 | |
| JP2003518129A (ja) | タンパク質チロシンホスファターゼ１ｂ（ｐｔｐ−１ｂ）のインヒビターとなるホスホン酸誘導体 | |
| JPWO2022129283A5 (enrdf_load_html_response) | ||
| CA2819603A1 (en) | Novel oxime derivatives as sphingosine 1-phosphate (s1p) receptor modulators | |
| JP2024543111A (ja) | 胃がんの治療に使用するための化合物 | |
| JP2013544833A (ja) | スフィンゴシン−１−リン酸（ｓ１ｐ）受容体モジュレーターとしての新規ピリジン誘導体 | |
| CN103354742A (zh) | 作为鞘氨醇1-磷酸(s1p)受体调节剂的新型肟氮杂环丁烷衍生物 | |
| CN103619828A (zh) | 作为1-磷酸鞘氨醇受体调节剂的苯基双环甲基胺衍生物 | |
| JPWO2022117477A5 (enrdf_load_html_response) | ||
| PT93468A (pt) | Processo para a preparacao de novas n-{(alquilamino)-alquil}-4,5-diaril-1h-pirazol-1-acetamidas uteis no tratamento de arritmia cardiaca | |
| JP2018528254A5 (enrdf_load_html_response) |